Article
The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings.
Basic & clinical pharmacology & toxicology - 1 Nov 2017
Taranu Adela, Asmar Khalil El, Colle Romain, Ferreri Florian, Polosan Mircea, David Denis, Becquemont Laurent, Corruble Emmanuelle, Verstuyft Céline
Abstract excerpt
The antidepressant venlafaxine is known to increase the turnover of cerebral monoamines, which are catabolized by the catechol-O-methyltransferase (COMT). The COMT (Val(108/158)Met, rs4680) genetic polymorphism affects the cerebral COMT activity. But whether this genetic polymorphism is associated with response to venlafaxine remains unclear. We assessed the impact of the COMT Val(108/158)Met, rs4680 genetic...
Read the complete abstract on PubMed